Granules India

Granules India Current Assets

The Current Assets of Granules India (GRANULES.NS) as of Oct 28, 2026 is 30.75 B INR. In the previous year, Current Assets was 28.74 B INR — a change of 6.98% (higher).

Current Assets

30.75 BINR

YoY

6.98%

Last updated:

Current Assets of Granules India is 2025 30.75 B INR. Current Assets of Granules India was 2024 28.74 B INR. It decreases by 6.98% higher compared to the previous year.

The Granules India Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
11.79 B INR
Jan 1, 2019
12.75 B INR
Jan 1, 2020
16.60 B INR
Jan 1, 2021
19.83 B INR
Jan 1, 2022
23.92 B INR
Jan 1, 2023
25.38 B INR
Jan 1, 2024
28.74 B INR
Jan 1, 2025
30.75 B INR
The Granules India Current Assets history
YEARCurrent AssetsYoY
30.75 BINR+6.98%
28.74 BINR+13.23%
25.38 BINR+6.11%
23.92 BINR+20.64%
19.83 BINR+19.47%
16.60 BINR+30.21%
12.75 BINR+8.09%
11.79 BINR+43.24%
8.23 BINR+1.17%
8.14 BINR+38.67%
5.87 BINR+78.05%
3.30 BINR+14.08%
2.89 BINR+11.03%
2.60 BINR+45.44%
1.79 BINR+2.76%
1.74 BINR+10.61%
1.57 BINR+30.62%
1.21 BINR+0.42%
1.20 BINR+60.43%
748.00 MINR-22.25%
962.00 MINR+65.29%
582.00 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Granules India Stock analysis

What does Granules India do? Granules India Ltd is a registered company in Hyderabad, India, specializing in the manufacturing of pharmaceutical active ingredients and formulations, product development, biotechnology research, and diagnostics. The company was established in 1984 and has become one of the leading suppliers of pharmaceutical active ingredients. The origins of Granules India Ltd began as a small company with only a few employees. In 1991, the company started production of Allantoin, a cosmetic active ingredient. Over the years, the company steadily grew and expanded its production capacities. In 1995, Granules India Ltd began manufacturing pharmaceutical active ingredients as part of its business. In the late 90s, the company expanded into other countries to distribute its products worldwide. Today, the main markets for Granules India Ltd are India, North America, Europe, and Asia. The company also has distribution offices in the USA, Europe, and Asia. Granules India Ltd has divided its business model into three main sectors: 1. Pharmaceutical Active Ingredients (APIs) - Granules India Ltd specializes in the manufacturing of pharmaceutical active ingredients used in drug production. The company produces a wide range of APIs, including Paracetamol, Ibuprofen, Metformin, and more. 2. Formulations - Granules India Ltd also produces various pharmaceutical formulations such as tablets, capsules, suspensions, and more. The company is able to develop and manufacture customized formulations according to customer requirements. 3. Biologics - In recent years, the company has also invested in biotechnology research, particularly in the development and manufacturing processes of biologics such as antibody drugs. The field of diagnostics is also covered. Granules India Ltd has established a strong position as a manufacturer of pharmaceutical active ingredients in recent years. The company supplies many of the major pharmaceutical companies worldwide. It has six production facilities in India that manufacture pharmaceutical active ingredients and formulations. The company also supplies to other manufacturers to support their production processes. In terms of products, Granules India Ltd offers a wide range of pharmaceutical active ingredients and formulations, all manufactured to the highest quality and in compliance with international standards. Some of the company's most well-known products are Paracetamol, Ibuprofen, Metformin, and Tramadol, used in pain management. The wide range of formulations includes tablets, capsules, suspensions, and more, used in various therapy areas such as cardiology, oncology, neurology, and infectious diseases. Overall, Granules India Ltd has achieved a leading position in the market for pharmaceutical active ingredients and formulations. The company has invested in research and development in recent years to expand its product range and provide customized solutions. Granules India Ltd remains committed to meeting the high standards in the pharmaceutical industry and developing innovative products to meet the needs of its customers. Granules India is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Granules India stock

Current Assets of Granules India is 30.75 B INR in 2025.

Current Assets of Granules India changed from 28.74 B INR to 30.75 B INR, representing a 6.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Granules India since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Granules India historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Granules India

All Key Metrics — Granules India